ENTA DB webcast disclosure: ENTA can earn $80M in pre-commercial regulatory milestones from ABBV for ABT-493 (ENTA’s next-gen pan-genotypic PI); this is separate from the $195M in regulatory milestones ENTA can earn from ABBV on ABT-450.
The combination of ABT-450 and ABT-530 is somewhat odd insofar as ABBV is testing ABT-530 (its next-gen NS5A inhibitor) and ABT-493 (ENTA’s next-gen PI) in GT1 patients in a safety/tolerability/dose-finding study where the new drugs are given for 3 days (#msg-94434033), and ABBV plans to develop the ABT-493 + ABT-530 combination in multiple genotypes (#msg-93372516).
Hence, ABBV’s rationale for testing ABT-530 with ABT-450 (rather than with ABT-493) in GT3 patients is presumably to get some data in GT3 quickly while waiting for the safety/tolerability data on the ABT-493 + ABT-530 combination that is needed to proceed to a phase-2 efficacy study of that regimen.
Market Data 
Markets 
AI
